Prognostic significance of hyperfibrinogenemia in patients with lower-risk myelodysplastic syndromes

  • Shinji Ogura
  • Shoichiro Yonei
  • Tomohiko Tanigawa
  • Masahiro Akimoto
  • Aki Sakurai
  • Yuriko Fujita
  • Chisako Ito
  • Yoshinobu Aisa
  • Tomonori NakazatoEmail author
Letter to the Editor

Dear Editor,

Fibrinogen is a protein produced following inflammation, and hyperfibrinogenemia is known as a poor prognostic factor in various tumors. In recent years, it has also been reported that hyperfibrinogenemia is a poor prognostic factor in diffuse large B-cell lymphoma [1]. However, whether hyperfibrinogenemia is a prognostic factor in patients with lower-risk myelodysplastic syndromes (MDS) remains unclear. We conducted the present study to assess the clinical significance of plasma fibrinogen levels in lower-risk MDS patients.

We retrospectively reviewed 87 patients who had been diagnosed with MDS and classified as having a low or int-1 IPSS score in our hospital between 2007 and 2017. A receiver operator characteristic (ROC) curve was used to generate a cutoff value for fibrinogen. The Kaplan-Meier method and univariate and multivariate analysis by Cox proportional hazards model were performed to assess the prognostic influence of the factors including the age (>60 years),...


Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statement of informed consent

Informed consent was obtained from the patients. The study was approved by the Ethics Committee of Yokohama Municipal Citizen’s Hospital.


  1. 1.
    Niu JY, Tian T, Zhu HY, Liang JH, Wu W, Cao L, Lu RN, Wang L, Li JY, Xu W (2018) Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma. Ann Hematol 97:1841–1849CrossRefGoogle Scholar
  2. 2.
    Ridker PM, Howard CP, Walter V et al (2012) Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126:2739–2748CrossRefGoogle Scholar
  3. 3.
    Taniguchi K, Karin M (2014) IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 26:54–74CrossRefGoogle Scholar
  4. 4.
    Pardanani A, Finke C, Lasho TL et al (2012) IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia 26:693–699CrossRefGoogle Scholar
  5. 5.
    Sahni A, Simpson-Hanidaris PJ, Sahni SK et al (2008) Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 6:176–183CrossRefGoogle Scholar
  6. 6.
    Sahni A, Khorana AA, Baggs RB et al (2006) FGF-2 binding to fibrinogen is required for augmented angiogenesis. Blood 107:126–131CrossRefGoogle Scholar
  7. 7.
    Sahni A, Francis CW (2000) Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 96:3772–3778CrossRefGoogle Scholar
  8. 8.
    Witsch E, Sela M, Yarden Y (2010) Roles for growth factors in cancer progression. Physiology (Bethesda) 25:85–101Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of HematologyYokohama Municipal Citizen’s HospitalYokohamaJapan

Personalised recommendations